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OBJECTIVES To investigate the hypothesis that prior angina pectoris confers protection from remodeling
occurring after myocardial infarction (MI), we analyzed echocardiograms from the Healing
and Early Afterload Reducing Therapy (HEART) trial.
BACKGROUND Ischemia occurring before MI has been shown to reduce infarct size in experimental models
and to improve outcomes in patients. The extent to which ischemia occurring before MI
influences subsequent changes in ventricular size and function is unclear.
METHODS We studied 283 patients enrolled in the HEART trial who had echocardiograms at days 1
and 90 after MI. Left ventricular (LV) dilation from days 1 to 90 was used as a measure of
LV remodeling. We explored the relationship between symptomatic angina occurring before
infarction and subsequent LV remodeling.
RESULTS In patients who reported angina (n  111) during the three months preceding MI, LV
volume change was 0.73  2.6 ml over the 90-day post-MI period, compared with 6.8 
2.6 ml for patients (n  172) without angina (p  0.017). In contrast, there were no
differences in changes in ejection fraction based on prior angina. Maximal creatine kinase was
significantly lower in patients with prior angina (2,119  1,729 vs. 2,701  2,088, p 
0.016). In a multivariate model, prior angina remained protective for ventricular remodeling
after adjusting for age, gender, baseline ejection fraction, Killip class, baseline end-diastolic
volume, and drug treatment group (p  0.042). However, the protective effect of pre-
infarction angina appeared to be attenuated in diabetic patients.
CONCLUSIONS Ischemic symptoms occurring before MI may protect against LV remodeling. These
protective effects may be secondary to recruitment of collaterals or ischemic preconditioning
of the myocardium, and they appear to be attenuated in diabetic patients. (J Am Coll
Cardiol 2004;43:1511–4) © 2004 by the American College of Cardiology Foundationeft ventricular (LV) remodeling—changes in the size and versus late ramipril therapy after MI (5). We have utilized
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ehape of the LV—is associated with increased morbidity
nd mortality post-myocardial infarction (MI) (1). The
xtent of LV remodeling can be influenced by initial infarct
ize, reperfusion therapy, and post-MI medical treatment
2). Episodes of ischemia occurring before MI (ischemic
reconditioning) have been shown in a number experimen-
al models to reduce infarct size (3). Furthermore, angina
See page 1515
ccurring before MI has been associated with improved
n-hospital outcome (4). The extent to which clinical
pisodes of ischemia occurring before MI influence subse-
uent LV function and remodeling is unknown.
The Healing and Early Afterload Reducing Therapy
HEART) trial was a randomized controlled trial of early
From the *Cardiovascular Division, Brigham and Women’s Hospital, Harvard
edical School, Boston, Massachusetts; †Green Lane Hospital, Auckland, New
ealand; ‡Cardiovascular Division, University of Toronto Health Network, Toronto,
anada; and the §University of Miami, Boca Raton, Florida. The HEART trial was
riginally supported by a grant from Hoechst-Marion Roussel.
Manuscript received July 18, 2003; revised manuscript received September 12,i003, accepted September 23, 2003.ata from HEART to test the hypothesis that symptomatic
schemic episodes occurring before MI influence the extent
f LV remodeling occurring after MI.
ETHODS
atients. The HEART study was a double-blind random-
zed trial of immediate versus delayed ramipril in 352
atients with anterior Q-wave MI. Patients underwent
chocardiographic examinations before randomization
within 24 h of MI) and at 14 and at 90 days after MI and
ere randomly assigned to receive one of three dosing
egimens of ramipril (placebo for 14 days, followed by
ull-dose [10 mg] ramipril; low-dose [0.625 mg] ramipril
or 90 days; or full-dose [10 mg] ramipril for 90 days).
nclusion and exclusion criteria and the details of the
itration scheme and patient characteristics have been pre-
iously described (5).
Serial echocardiographic data were available for 286
atients. Patients with initial echocardiograms of insuffi-
ient quality or patients who were alive at 90 days but in
hom 90-day echocardiograms were not available were
xcluded from these analyses. Of the 352 patients enrolled
n the original study, 48 did not have echocardiograms of
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Angina Pectoris and LV Remodeling May 5, 2004:1511–4ufficient quality for analysis, and 18 (including 13 deaths)
id not have all three echocardiograms.
ssessment of ischemic episode. At enrollment in
EART, the local investigator administered a baseline
ntake questionnaire asking whether the patient had expe-
ienced angina within the past three months. An additional
uestion determined whether angina occurred at rest or had
wakened the patient from sleep. Determination of symp-
omatic ischemia was made in 283 patients who had
chocardiograms performed at days 1 and 90.
chocardiographic analysis. Echocardiographic measure-
ents were made in triplicate on a Nova Microsonics
orkstation as previously described. Endocardial borders
rom end-diastolic and end-systolic frames were digitized
anually, and LV volumes were assessed with the modified
impson’s rule method. Infarct segment size was assessed by
anually tracing the akinetic or dyskinetic segment, which
as expressed as a percentage of endocardial perimeter. The
eproducibility of the echocardiographic measurements has
een previously reported (5).
tatistical analyses. Patients were categorized into two
roups depending on whether or not they experienced clinical
ngina during the three months preceding MI. Patients were
urther categorized depending on whether they had rest or
xertional angina. Left ventricular remodeling was defined as
he increase in ventricular end-diastolic volume between days 1
Abbreviations and Acronyms
CK  creatine kinase
HEART  Healing and Early Afterload Reducing
Therapy trial
LV  left ventricle/ventricular
MI  myocardial infarction
Table 1. Clinical and Echocardiographic Char
Angina
Age
Male
Female
Prior MI
Diabetes
Beta-blocker
Ca-blocker
Nitrates
Aspirin
Thrombolysis
Primary PTCA
Maximum CK
Baseline LV end-diastolic volume (ml)
Baseline LV end-systolic volume (ml)
Baseline ejection fraction (%)
Baseline infarct segment length (%)
Change in end-diastolic volume (days 1 to 90)
Change in ejection fraction (days 1 to 90)
CK  creatine kinase; LV  left ventricular; MI  myo
angioplasty.nd 90 and treated as a continuous variable. Differences
etween means when normally distributed were compared
ith the Student t test and with the Wilcoxon rank sum test
hen not normally distributed. Comparison of groups was
erformed with analysis of variance. Multivariate linear regres-
ion was used to assess the relationship between stable angina
receding MI and post-MI ventricular remodeling. Values are
xpressed as mean  SD. A value p  0.05 was considered
tatistically significant.
ESULTS
linical and echocardiographic characteristics of patients
ith (n  111) and without (n  172) stable angina in the
hree months preceding MI are shown in Table 1. Previous
istory of MI and use of anti-anginal medications, including
spirin, nitrates, beta-blockade, and calcium channel block-
rs, were more common in patients with a history of angina
n the three months preceding MI. Stable angina preceding
I was associated with both reduced maximal creatine
inase (CK) (2,701  2,088 vs. 2,119  1,729, p  0.016)
nd decreased infarct segment length (26.9  11.2% vs.
4.6  9.8%, p  0.08), although ejection fractions were
imilar in the two groups (52.6  9.4% vs. 52.4  9.8%, p
0.81). There were no differences in medication use
etween groups at 90 days.
Left ventricular end-diastolic volume from days 1 to 90
ncreased by 6.8  2.6 ml in patients without prior stable
ngina, compared with a 0.73  2.6 ml decrease in patients
ith prior stable angina (p  0.017) (Table 1). There was
o difference in change in ejection fraction over the 90-day
eriod in the two groups. Patients with angina at rest or
uring sleep demonstrated less remodeling than either
atients with exertional angina or patients with no angina
analysis of variance, p  0.049) (Fig. 1).
stics of Patients With and Without Prior
o Angina
n  172)
Angina
(n  111) p Value
9.4  12.4 59.4  12.2 0.97
38 (80%) 85 (77%) 0.46
34 (20%) 26 (23%) 0.46
20 (11%) 24 (21%) 0.02
36 (21%) 22 (20%) 0.82
16 (9%) 27 (24%) 0.001
18 (10%) 20 (18%) 0.07
4 (2%) 13 (11%) 0.001
34 (20%) 39 (35%) 0.004
56 (88%) 97 (87%) 0.20
49 (28%) 29 (26%) 0.51
01  2,088 2,119  1,729 0.016
3.1  35.6 107.3  36.0 0.32
9.9  24.7 52.3  26.0 0.42
2.6  9.4 52.4  9.8 0.81
6.9  11.2 24.6  9.8 0.08
6.8  25.7 0.73  26.1 0.017
4.4  9.1 4.5  10.6 0.96
infarction; PTCA  percutaneous transluminal coronaryacteri
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May 5, 2004:1511–4 Angina Pectoris and LV RemodelingIn a multivariate model, prior stable angina remained
redictive of less remodeling after adjusting for age, gender,
aseline ejection fraction, Killip class, history of diabetes,
aseline end-diastolic volume, and drug treatment (p 
.042), but not after including maximal CK in the model.
o determine whether patients with prior stable angina
ere more likely to obtain medical treatment early, we
ompared the time until thrombolysis in the 205 patients in
his cohort who received thrombolytic therapy. Patients
ith prior stable angina had slightly longer times to throm-
olysis (3.9 6.0 vs. 3.4 2.8 h, p 0.41), although these
ere not significantly different.
The prevalence of diabetes was similar in both groups.
e tested the hypothesis that decreased reporting of isch-
mic episodes in diabetic patients might account for in-
reased remodeling in the group that did not report prior
ngina. There were no differences in the extent of remod-
ling in diabetics with and without stable angina (4.1  2.6
s. 4.7 2.5, p 0.86). Thus, the protective effect of stable
ngina preceding MI appeared to be attenuated in diabetics
Table 2). There was no interaction between stable angina
nd remodeling amongst diabetics (p  0.19).
ISCUSSION
he results of this analysis demonstrate that patients with
ymptomatic stable angina preceding MI demonstrate less
entricular remodeling than do patients without prior symp-
omatic stable angina. Furthermore, patients with rest
ngina appear to be more protected than patients with
xertional angina. In addition, stable angina preceding MI
ppears to be associated with decreased infarct size, as
easured by peak CK and echocardiographic estimates of
nfarct segment length, suggesting that angina preceding
Figure 1. Change in end-diastolic volume between days 1 and 90.
able 2. Left Ventricular Dilation From Days 1 to 90 in
iabetics and Non-Diabetics With and Without Angina
No Angina  in
Volume (ml)
Angina  in
Volume (ml)
p
Value
iabetics
(n  58)
4.1  2.6 (n  36) 4.7  2.5 (n  22) 0.86
on-diabetics
(n  227)
7.8  2.1 (n  89) 1.9  2.1 (n  138) 0.007tI may confer protective benefits on remodeling by limit-
ng the size of the infarct itself. Although previous studies
ave demonstrated improvement in hospital outcome in
atients with symptomatic ischemia occurring before MI,
his study demonstrates that structural changes in the LV
ay be affected by prior symptomatic ischemia in humans.
A reduction in infarct size as a result of previous exposure to
rief episodes of ischemia has been referred to as ischemic
reconditioning (6) and this phenomenon is supported by
umerous experimental models (2,3). The cardioprotective
ffects of this phenomenon have been attributed to reduced
nergy demand in ischemic preconditioned myocardial tissue
6). The mechanisms eliciting these changes are complex and
till unclear. Adenosine, bradykinin, and opioids have all been
ocumented to accumulate during episodes of ischemia and are
ssociated with preconditioning effects via interaction with
econd messenger systems, specifically protein kinase C and
ATP channels (6–8). Brief episodes of ischemia are often
ssociated with protein kinase C activation, which stimulates
pening of mitochondrial KATP channels (9). A consistent
nding has been that the cardioprotective manifestations ap-
ear to be independent of coronary collateral flow (2).
Stable angina preceding MI represents a clinical correlate
f ischemic preconditioning. Several clinical studies have
uggested that stable angina occurring before MI may
onfer cardioprotective effects. Both the Thrombolysis In
yocardial Infarction (TIMI)-4 and -9 thrombolytic trials
emonstrated that angina might reduce infarct size, improve
urvival, improve left ventricular function and reduce ar-
hythmias (4,10). Of 153 patients, of whom 100 had stable
ngina preceding infarction, angina was associated with a
ower incidence of ventricular arrhythmia, pump failure,
ardiac rupture, and a lower in-hospital mortality rate (10).
n addition, peak CK was also lower in patients with angina,
nd in a subset of 65 patients who underwent left ventricu-
ography, patients with angina showed improved function
nd reduced ventricular volumes (10). Although this assess-
ent was performed early after infarction, our data suggest
hat symptomatic ischemia occurring before infarction con-
ers sustained benefit as well. Although the maximal peak
K in the angina group in the present study was less when
ompared to the non-angina group, ejection fractions were
imilar. This may be explained by the fact that early ejection
raction may be more strongly influenced by the extent of
yocardial stunning than by the extent of necrosis (11).
In the current study, exertional angina was associated with
ess of a protective effect than rest or sleep angina. It is possible
hat individuals experiencing rest or sleep angina may be
aving these events quite proximal to infarction; additionally,
hese individuals may have an overall greater ischemic burden
12). Alternatively, patients experiencing exertional angina may
ave elevated circulating levels of catecholamines that may
vercome any benefits of preconditioning (13,14).
Although stable angina preceding MI offered protection
rom subsequent ventricular remodeling in the overall cohort,
his effect was not apparent in diabetic patients. We cannot rule
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Angina Pectoris and LV Remodeling May 5, 2004:1511–4ut the possibility that this finding was due to reporting bias, as
iabetic patients may be less likely to report ischemic symp-
oms even though they may have more total ischemic episodes.
f this were the case in our diabetic cohort, the relationship
etween angina and remodeling might be obscured. Similar
ifferential findings between diabetics and nondiabetics were
hown in a recent post-MI study of 121 diabetic patients in
hich there were no significant differences in peak CK, LV
jection fraction, or in-hospital mortality observed between
roups with or without prodromal angina (15). Although the
ifferential findings may have been partly explained by delayed
ospital presentation in diabetics, evidence from various animal
ased studies suggests that diabetic hearts are less sensitive to
he effects of preconditioning (16,17). Diabetes is thought to
nterfere with the biochemical pathways of preconditioning
18,19), rendering the diabetic myocardium more vulnerable to
epeated bouts of ischemia (20). Sulphonylureas are docu-
ented to antagonize KATP channels and this may also
ontribute to preconditioning insensitivity (9,21). Other con-
ounding factors include impaired perception of ischemia
ssociated with high ischemic burden and resulting in late
resentations and more complete infarctions. A combination
f reporting bias, delayed presentations, and reduced sensitivity
o preconditioning may explain our findings within the diabetic
roup.
Some potential limitations of this analysis must be noted.
ur ability to determine whether a patient had prior angina
as dependent on an accurate history and recording of this
nformation by the site investigator. We considered two
otential biases that might have influenced the relationship
etween prior stable angina and remodeling. First, we consid-
red the possibility that patients who had experienced prior
table angina were more likely to seek and receive prompt
edical attention. This did not appear to be the case in
atients who received thrombolysis; the time to thrombolysis
as in fact shorter in patients who had not had prior angina
3.9  6.0 h vs. 3.4  2.8 h). Second, individuals with
mpaired pain perception might be expected to demonstrate
reater remodeling owing to unrecognized multiple events and
ate presentation for treatment; this could have confounded the
esults observed amongst diabetics, although it apparently did
ot. Additionally, we cannot exclude the possibility that the
elationship between prior angina and remodeling may be
ifferent in patients with larger, more extensive infarcts.
In summary, stable angina preceding MI appears to protect
gainst subsequent ventricular remodeling. This effect appears
o be attenuated in diabetic patients. Whether this finding is
ue to reporting bias or an intrinsic resistance to precondition-
ng in the diabetic heart requires further study.
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